Genscript Biotech Reports Significant Profit Boost from Cell Therapy Deconsolidation

Genscript Biotech ( (HK:1548) ) has provided an update.

Genscript Biotech reported a significant increase in profit for the year ended December 31, 2024, primarily due to a gain from the deconsolidation of its cell therapy business, amounting to approximately US$3.2 billion. Despite a stable gross profit and a modest revenue growth of 6.1%, the adjusted net profit from continuing operations saw a slight increase of 2.9%, reflecting the company’s strategic adjustments and financial resilience.

More about Genscript Biotech

Genscript Biotech Corporation, incorporated in the Cayman Islands, operates in the biotech industry. The company focuses on providing a range of biotechnology products and services, likely including cell therapy, as indicated by the deconsolidation of its cell therapy business.

YTD Price Performance: 13.39%

Average Trading Volume: 3,834

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $3.72B

See more insights into 1548 stock on TipRanks’ Stock Analysis page.